Immunoforge Co. Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2017-05-29
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immunoforge.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
Phase 2
Recruiting
- Conditions
- Idiopathic Inflammatory MyopathiesDermatomyositisPolymyositis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Immunoforge Co. Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT05833711
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
News
No news found